SCHEMBL15041222

SCHEMBL15041222

O=c1ccc2cnc(Nc3ccc(OC4CCNC4)cc3)nc2n1Cc1cnccc1-c1ccncc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 17/20 0.47
CCND1 P24385 17/20 0.47
CCND2 P30279 17/20 0.47
CCND3 P30281 17/20 0.47
PRKCZ Q05513 1/20 0.41
CCNE2 O96020 2/20 0.39
FGFR1 P11362 2/20 0.39
CCNA2 P20248 2/20 0.39
FGFR2 P21802 2/20 0.39
FGFR4 P22455 2/20 0.39
FGFR3 P22607 2/20 0.39
CCNE1 P24864 2/20 0.39
CDK2 P24941 2/20 0.39
CCNA1 P78396 2/20 0.39
CCNB2 O95067 1/20 0.39
CDK1 P06493 1/20 0.39
SRC P12931 1/20 0.39
CCNB1 P14635 1/20 0.39
CCNB3 Q8WWL7 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15034925 0.95 CDK4 (0.46) CDK4CCND1CCND2CCND3PRKCZ
SCHEMBL15277169 0.87 CDK4 (0.44) CDK4CCND1CCND2CCND3PRKCZ
SCHEMBL15035894 0.85 CDK4 (0.44) CDK4CCND1CCND2CCND3PRKCZ
SCHEMBL15041632 0.84 CDK4 (0.43) CDK4CCND1CCND2CCND3PRKCZ
SCHEMBL15034817 0.80 CDK4 (0.45) CDK4CCND1CCND2CCND3CCNE2
SCHEMBL15034987 0.79 CDK4 (0.45) CDK4CCND1CCND2CCND3CCNE2
SCHEMBL10192632 0.78 CDK4 (0.46) CDK4CCND1CCND2CCND3CCNE2
SCHEMBL15035814 0.78 CDK4 (0.42) CDK4CCND1CCND2CCND3CCNE2
SCHEMBL15041770 0.77 CDK4 (0.47) CDK4CCND1CCND2CCND3CCNE2
SCHEMBL10192629 0.77 CDK4 (0.48) CDK4CCND1CCND2CCND3CCNE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130231348-A1 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS AFRAXIS, INC. (US) 2013-09-05 US disclosed
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER AFRAXIS, INC. (US) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130231348-A1 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS PAK2, PAK3, PAK5 CDK4 408/4885CCND1 3984/4885CCND2 3905/4885
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER PAK5, PAK2, PAK6 CDK4 404/4885CCND1 2153/4885CCND2 2332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.